News | May 16, 2011

Occlutech Wins German Supreme Court Ruling Against AGA/St. Jude Medical

May 16, 2011 - The German Supreme Court (BGH) declared a structural heart occluder patent case to be invalid. In the ruling by the BGH, the court does not see any basis for AGA/St. Jude's claim that the Occlutech atrial septal defects and patent foramen ovale (ASD and PFO) occluders violate any patent brought forward in the litigation and declares earlier German ruling to the contrary invalid.

The German Supreme Court ruling is similar in many aspects to the first instance ruling in the UK, which was confirmed by the appeal court in the UK in mid 2010. The UK ruling is final, as the UK supreme court did not allow an appeal requested by AGA. The favorable German ruling is also similar to first instance as well as appeal court decisions in The Hague in The Netherlands, the last one obtained at the end of 2010, as well as a district court ruling in Stockholm, Sweden, obtained in March 2011.

Throughout the litigation, Occlutech's owners and partners have funded work in maintaining and substantially strengthening Occlutech's own patent position. Meanwhile, a full pipeline of new technologies and products has been developed. In 2011 and 2012, Occlutech expects to launch additional occluders for indications such as patent ductus artery (PDA) and ventricular septal defect (VSD) in addition to second generation ASD and PFO occluders. Also, an innovative left atrial appendage (LAA) occluder and a new generation of stent grafts and cardiac valve intervention technologies are being developed.

Occlutech intends to initiate litigation for substantial damages against AGA/St. Jude.

Related Content

FDA Approves Abbott's Amplatzer Piccolo Occluder
News | Structural Heart Occluders | January 16, 2019
Abbott announced the U.S. Food and Drug Administration (FDA) approved the Amplatzer Piccolo Occluder to treat patent...
FDA Approves Gore Cardioform Septal Occluder for PFO Closure Prevent Recurrent Ischemic Stroke
Technology | Structural Heart Occluders | April 03, 2018
April 3, 2018 — Following the unprecedented Gore REDUCE Clinical Study conclusion that closure of patent foramen oval
Videos | Structural Heart Occluders | November 08, 2017
John Rhodes, M.D., co-director of the adult congenital heart program, Medical University of South Carolina, is the pr
Videos | Structural Heart Occluders | September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
University of Alabama at Birmingham, Amplatzer PFO Occluder, first implementation
News | Structural Heart Occluders | February 15, 2017
Doctors at the University of Alabama at Birmingham have implemented the first U.S. Food and Drug Administration (FDA)-...
Amplatzer PFO Occluder, St. Jude Medical, Baylor Heart and Vascular Services, Fort Worth, Texas, first patients
News | Structural Heart Occluders | February 01, 2017
Baylor Heart and Vascular Services at Fort Worth in November became the first program in Texas to implant the Amplatzer...
RESPECT trial, Amplatzer PFO Occluder, St. Jude Medical, TCT 2016
News | Structural Heart Occluders | November 02, 2016
St. Jude Medical Inc. announced the long-term data from RESPECT, a landmark trial, during a First Report session at the...
St. Jude Medical, Amplatzer PFO Occluder, FDA approval, U.S. launch
Technology | Structural Heart Occluders | November 02, 2016
St. Jude Medical Inc. announced this week the U.S. Food and Drug Administration (FDA) approval and launch of the...
PFO closure, patent foramen ovale, AAN recommendation, American Academy of Neurology, stroke patients
News | Structural Heart Occluders | August 08, 2016
Updated recommendations from the American Academy of Neurology (AAN) states that catheter-based closure should not be...
Overlay Init